J.W. Cole Advisors, Inc. Vertex Pharmaceuticals Inc Transaction History
J.W. Cole Advisors, Inc.
- $3.14 Billion
- Q1 2025
A detailed history of J.W. Cole Advisors, Inc. transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, J.W. Cole Advisors, Inc. holds 1,753 shares of VRTX stock, worth $642,544. This represents 0.03% of its overall portfolio holdings.
Number of Shares
1,753
Previous 709
147.25%
Holding current value
$642,544
Previous $285,000
197.89%
% of portfolio
0.03%
Previous 0.01%
Shares
11 transactions
Others Institutions Holding VRTX
# of Institutions
1,816Shares Held
232MCall Options Held
1.49MPut Options Held
1.07M-
Capital World Investors Los Angeles, CA28.5MShares$10.5 Billion2.34% of portfolio
-
Vanguard Group Inc Valley Forge, PA23.5MShares$8.61 Billion0.21% of portfolio
-
Black Rock Inc. New York, NY21.3MShares$7.81 Billion0.23% of portfolio
-
Capital Research Global Investors Los Angeles, CA14.5MShares$5.33 Billion1.6% of portfolio
-
State Street Corp Boston, MA11.8MShares$4.32 Billion0.24% of portfolio
About VERTEX PHARMACEUTICALS INC
- Ticker VRTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 256,691,008
- Market Cap $94.1B
- Description
- Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...